🇺🇸 FDA
Patent

US 12351834

Compositions and methods for the treatment of ornithine transcarbamylase deficiency

granted A61KA61K2039/51A61K31/221

Quick answer

US patent 12351834 (Compositions and methods for the treatment of ornithine transcarbamylase deficiency) held by ARCTURUS THERAPEUTICS, INC. expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARCTURUS THERAPEUTICS, INC.
Grant date
Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K2039/51, A61K31/221, A61K48/00, A61K48/0033